Boston Scientific (BSX) announced it has entered into a definitive agreement to acquire Valencia Technologies, a privately held medical technology company focused on the development and commercialization of innovative solutions to treat bladder dysfunction. The company’s eCoin System is an implantable tibial nerve stimulation device for the treatment of urge urinary incontinence, a common symptom of overactive bladder. Boston Scientific expects to complete the acquisition in the first half of 2026, subject to customary closing conditions. The transaction is expected to have an immaterial impact on adjusted earnings per share in 2026 and is expected to be more dilutive on a GAAP basis due to acquisition-related net charges and amortization expense. Specific terms of the transaction have not been disclosed.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target lowered to $112 from $124 at Goldman Sachs
- Boston Scientific’s AXIOS™ Gastroenterostomy Trial Paused: What Investors Should Watch
- Boston Scientific’s RAINBOW Study: What the Hot AXIOS™ Update Means for Investors
- Becton Dickinson price target raised to $215 from $210 at Stifel
- Boston Scientific price target lowered to $112 from $113 at Evercore ISI